The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Personalizing Cancer Drugs-Global Market Insights and Sales Trends 2025

Personalizing Cancer Drugs-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1839635

No of Pages : 112

Ask Your Query

Synopsis

The global Personalizing Cancer Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Personalizing Cancer Drugs in various end use industries.

The expanding demands from the Breast Cancer, Blood Cancer, Gastrointestinal Cancer and Prostate Cancer, are propelling Personalizing Cancer Drugs market. Immunotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations.

Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Personalizing Cancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Personalizing Cancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Personalizing Cancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Personalizing Cancer Drugs sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Personalizing Cancer Drugs covered in this report include Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb and Celgene Corporation, etc.

The global Personalizing Cancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

  • Bayer
  • GlaxoSmithKline
  • Novartis
  • Sanofi
  • Pfizer
  • Amgen
  • Merck
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Ariad Pharmaceuticals
  • Eli Lilly
  • Hoffmann-La Roche
  • Boehringer Ingelheim
  • Johnson and Johnson
  • Teva Pharmaceuticals

Global Personalizing Cancer Drugs market, by region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Personalizing Cancer Drugs market, Segment by Type:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Hormone Therapy
  • Others

Global Personalizing Cancer Drugs market, by Application

  • Breast Cancer
  • Blood Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Skin Cancer
  • Lung Cancer
  • Others

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Personalizing Cancer Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index

1 Market Overview of Personalizing Cancer Drugs
1.1 Personalizing Cancer Drugs Market Overview
1.1.1 Personalizing Cancer Drugs Product Scope
1.1.2 Personalizing Cancer Drugs Market Status and Outlook
1.2 Global Personalizing Cancer Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Personalizing Cancer Drugs Market Size by Region (2018-2029)
1.4 Global Personalizing Cancer Drugs Historic Market Size by Region (2018-2023)
1.5 Global Personalizing Cancer Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Personalizing Cancer Drugs Market Size (2018-2029)
1.6.1 North America Personalizing Cancer Drugs Market Size (2018-2029)
1.6.2 Europe Personalizing Cancer Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Personalizing Cancer Drugs Market Size (2018-2029)
1.6.4 Latin America Personalizing Cancer Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Personalizing Cancer Drugs Market Size (2018-2029)
2 Personalizing Cancer Drugs Market by Type
2.1 Introduction
2.1.1 Immunotherapy
2.1.2 Targeted Therapy
2.1.3 Chemotherapy
2.1.4 Hormone Therapy
2.1.5 Others
2.2 Global Personalizing Cancer Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Personalizing Cancer Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Personalizing Cancer Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Personalizing Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Personalizing Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Personalizing Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Personalizing Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Personalizing Cancer Drugs Revenue Breakdown by Type (2018-2029)
3 Personalizing Cancer Drugs Market Overview by Application
3.1 Introduction
3.1.1 Breast Cancer
3.1.2 Blood Cancer
3.1.3 Gastrointestinal Cancer
3.1.4 Prostate Cancer
3.1.5 Skin Cancer
3.1.6 Lung Cancer
3.1.7 Others
3.2 Global Personalizing Cancer Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Personalizing Cancer Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Personalizing Cancer Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Personalizing Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Personalizing Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Personalizing Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Personalizing Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Personalizing Cancer Drugs Revenue Breakdown by Application (2018-2029)
4 Personalizing Cancer Drugs Competition Analysis by Players
4.1 Global Personalizing Cancer Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Personalizing Cancer Drugs as of 2022)
4.3 Date of Key Players Enter into Personalizing Cancer Drugs Market
4.4 Global Top Players Personalizing Cancer Drugs Headquarters and Area Served
4.5 Key Players Personalizing Cancer Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Personalizing Cancer Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Personalizing Cancer Drugs Products, Services and Solutions
5.1.4 Bayer Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Bayer Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Personalizing Cancer Drugs Products, Services and Solutions
5.2.4 GlaxoSmithKline Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis Personalizing Cancer Drugs Products, Services and Solutions
5.3.4 Novartis Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Personalizing Cancer Drugs Products, Services and Solutions
5.4.4 Sanofi Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Personalizing Cancer Drugs Products, Services and Solutions
5.5.4 Pfizer Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Amgen
5.6.1 Amgen Profile
5.6.2 Amgen Main Business
5.6.3 Amgen Personalizing Cancer Drugs Products, Services and Solutions
5.6.4 Amgen Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Personalizing Cancer Drugs Products, Services and Solutions
5.7.4 Merck Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Bristol-Myers Squibb
5.8.1 Bristol-Myers Squibb Profile
5.8.2 Bristol-Myers Squibb Main Business
5.8.3 Bristol-Myers Squibb Personalizing Cancer Drugs Products, Services and Solutions
5.8.4 Bristol-Myers Squibb Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Bristol-Myers Squibb Recent Developments
5.9 Celgene Corporation
5.9.1 Celgene Corporation Profile
5.9.2 Celgene Corporation Main Business
5.9.3 Celgene Corporation Personalizing Cancer Drugs Products, Services and Solutions
5.9.4 Celgene Corporation Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Celgene Corporation Recent Developments
5.10 Ariad Pharmaceuticals
5.10.1 Ariad Pharmaceuticals Profile
5.10.2 Ariad Pharmaceuticals Main Business
5.10.3 Ariad Pharmaceuticals Personalizing Cancer Drugs Products, Services and Solutions
5.10.4 Ariad Pharmaceuticals Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Ariad Pharmaceuticals Recent Developments
5.11 Eli Lilly
5.11.1 Eli Lilly Profile
5.11.2 Eli Lilly Main Business
5.11.3 Eli Lilly Personalizing Cancer Drugs Products, Services and Solutions
5.11.4 Eli Lilly Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Eli Lilly Recent Developments
5.12 Hoffmann-La Roche
5.12.1 Hoffmann-La Roche Profile
5.12.2 Hoffmann-La Roche Main Business
5.12.3 Hoffmann-La Roche Personalizing Cancer Drugs Products, Services and Solutions
5.12.4 Hoffmann-La Roche Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Hoffmann-La Roche Recent Developments
5.13 Boehringer Ingelheim
5.13.1 Boehringer Ingelheim Profile
5.13.2 Boehringer Ingelheim Main Business
5.13.3 Boehringer Ingelheim Personalizing Cancer Drugs Products, Services and Solutions
5.13.4 Boehringer Ingelheim Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Boehringer Ingelheim Recent Developments
5.14 Johnson and Johnson
5.14.1 Johnson and Johnson Profile
5.14.2 Johnson and Johnson Main Business
5.14.3 Johnson and Johnson Personalizing Cancer Drugs Products, Services and Solutions
5.14.4 Johnson and Johnson Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 Johnson and Johnson Recent Developments
5.15 Teva Pharmaceuticals
5.15.1 Teva Pharmaceuticals Profile
5.15.2 Teva Pharmaceuticals Main Business
5.15.3 Teva Pharmaceuticals Personalizing Cancer Drugs Products, Services and Solutions
5.15.4 Teva Pharmaceuticals Personalizing Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Teva Pharmaceuticals Recent Developments
6 North America
6.1 North America Personalizing Cancer Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Personalizing Cancer Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Personalizing Cancer Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Personalizing Cancer Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Personalizing Cancer Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Personalizing Cancer Drugs Market Dynamics
11.1 Personalizing Cancer Drugs Industry Trends
11.2 Personalizing Cancer Drugs Market Drivers
11.3 Personalizing Cancer Drugs Market Challenges
11.4 Personalizing Cancer Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock